- Home
- ACRS vs CURI Comparison
ACRS vs CURI Comparison
Compare ACRS & CURI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- CURI
- Stock Information
- Founded
- ACRS 2012
- CURI N/A
- Country
- ACRS United States
- CURI United States
- Employees
- ACRS N/A
- CURI N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- CURI Movies/Entertainment
- Sector
- ACRS Health Care
- CURI Consumer Discretionary
- Exchange
- ACRS Nasdaq
- CURI Nasdaq
- Market Cap
- ACRS 127.6M
- CURI 144.8M
- IPO Year
- ACRS 2015
- CURI N/A
- Fundamental
- Price
- ACRS $1.14
- CURI $3.17
- Analyst Decision
- ACRS Strong Buy
- CURI Strong Buy
- Analyst Count
- ACRS 7
- CURI 1
- Target Price
- ACRS $11.67
- CURI $3.00
- AVG Volume (30 Days)
- ACRS 968.2K
- CURI 204.0K
- Earning Date
- ACRS 05-06-2025
- CURI 05-06-2025
- Dividend Yield
- ACRS N/A
- CURI 2.82%
- EPS Growth
- ACRS N/A
- CURI N/A
- EPS
- ACRS N/A
- CURI N/A
- Revenue
- ACRS $18,720,000.00
- CURI $51,134,000.00
- Revenue This Year
- ACRS N/A
- CURI $14.96
- Revenue Next Year
- ACRS $425.96
- CURI $10.06
- P/E Ratio
- ACRS N/A
- CURI N/A
- Revenue Growth
- ACRS N/A
- CURI N/A
- 52 Week Low
- ACRS $0.95
- CURI $0.94
- 52 Week High
- ACRS $5.17
- CURI $3.22
- Technical
- Relative Strength Index (RSI)
- ACRS 27.21
- CURI 64.78
- Support Level
- ACRS $1.05
- CURI $2.30
- Resistance Level
- ACRS $1.23
- CURI $2.71
- Average True Range (ATR)
- ACRS 0.11
- CURI 0.23
- MACD
- ACRS -0.01
- CURI 0.03
- Stochastic Oscillator
- ACRS 16.82
- CURI 91.68
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About CURI CuriosityStream Inc.
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. Its mission is to provide premium real entertainment that informs, enchants, and inspires. Its product and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, Enterprise Subscriptions, and Others. The majority of the revenue comes from the Direct to direct-to-consumer business.